Literature DB >> 26911798

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

J H Levy1, W Ageno2, N C Chan3, M Crowther4, P Verhamme5, J I Weitz4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26911798     DOI： 10.1111/jth.13227

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  72 in total

1.  The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors:  Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal:  P T       Date:  2017-11

2.  Italian intersociety consensus on DOAC use in internal medicine.

Authors:  Domenico Prisco; Walter Ageno; Cecilia Becattini; Armando D'Angelo; Giovanni Davì; Raimondo De Cristofaro; Francesco Dentali; Giovanni Di Minno; Anna Falanga; Gualberto Gussoni; Luca Masotti; Gualtiero Palareti; Pasquale Pignatelli; Roberto M Santi; Francesca Santilli; Mauro Silingardi; Antonella Tufano; Francesco Violi
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

3.  Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.

Authors:  Sophie Testa; Walter Ageno; Emilia Antonucci; Rossella Morandini; Jan Beyer-Westendorf; Maurizio Paciaroni; Marc Righini; Piera Sivera; Peter Verhamme; Vittorio Pengo; Daniela Poli; Gualtiero Palareti
Journal:  Intern Emerg Med       Date:  2018-05-22       Impact factor: 3.397

Review 4.  The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

Authors:  Maureane Hoffman; Joshua N Goldstein; Jerrold H Levy
Journal:  Int J Emerg Med       Date:  2018-12-03

Review 5.  New Oral Anticoagulants and Their Reversal Agents.

Authors:  Andrea Morotti; Joshua N Goldstein
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

6.  Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.

Authors:  Romain Siriez; Lütfiye Alpan; Kossay Elasaad; Philippe Devel; Julie Laloy; Jean-Michel Dogné; Jonathan Douxfils
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

Review 7.  Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.

Authors:  Michela Giustozzi; Melina Verso; Giancarlo Agnelli; Cecilia Becattini
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

Review 8.  Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence.

Authors:  Arthur Bracey; Wassim Shatila; James Wilson
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-09-30

9.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

Review 10.  Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

Authors:  Michelangelo Sartori; Benilde Cosmi
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.